RCERecce Pharmaceuticals Ltd

RCE Stock Price, Valuation & Chart | Recce Pharmaceuticals Ltd

Compare

$0.360+0.00 (+0.00%)

At close · 02 Sept 2026, 06:10 am

Sector: Healthcare Industry: Biotechnology RCE intrinsic value RCE calculated fair value vs price Website

Overview Financials Dividends Ratios

RCE Historical price chart

RCE Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization110.08M

PE Ratio-3.15

EPS-0.11

Trading Volume41.26K

Today's High/Low0.37/0.35

Dividend Yield0.00

52 Week High/Low0.73/0.35

Shares Outstanding305.77M

RCE Financial Statement

RCE Analyst ratings

Buy

Strong buy

Buy

Hold

Sell

Strong sell

Based on 0 analysts giving stock ratings to RCE in the past 3 months.

RCE Analysis & performance metrics

RCE Company profile

Recce Pharmaceuticals Ltd, a biotechnology company, engages in the research, development, and commercialization of synthetic antiinfectives in Australia, the United States,…

Recce Pharmaceuticals Ltd, a biotechnology company, engages in the research, development, and commercialization of synthetic antiinfectives in Australia, the United States, and the United Kingdom. The company's lead candidate is RECCE 327 to treat blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. It also develops RECCE 529, a…

RCE Management team

Name

Position

Maggie Niewidok

Company Secretary

John K. A. Prendergast Ph.D.

Executive Chairman of the Board

James Hamilton-Bray Graham GAICDCEO

Chief Executive Officer, MD & Executive Director

Michele Keryn Dilizia BA (Journ), BSc (Med Sci)CTO

Chief Scientific Director & Executive Director

Justin WardCTO

Principal Quality Chemist & Executive Director

Arthur Kollaras

Principal Engineer & Head of Manufacturing

Alan W. Dunton B.Sc., M.D.CTO

Chief Medical Advisor & Independent Non Executive Director

Justin ReynoldsCFO

Chief Financial Officer

Name

Position

Maggie Niewidok

Company Secretary

John K. A. Prendergast Ph.D.

Executive Chairman of the Board

James Hamilton-Bray Graham GAICDCEO

Chief Executive Officer, MD & Executive Director

Michele Keryn Dilizia BA (Journ), BSc (Med Sci)CTO

Chief Scientific Director & Executive Director

Justin WardCTO

Principal Quality Chemist & Executive Director

Arthur Kollaras

Principal Engineer & Head of Manufacturing

Alan W. Dunton B.Sc., M.D.CTO

Chief Medical Advisor & Independent Non Executive Director

Justin ReynoldsCFO

Chief Financial Officer

Management Team

Maggie Niewidok

Company Secretary

John K. A. Prendergast Ph.D.

Executive Chairman of the Board

James Hamilton-Bray Graham GAICDCEO

Chief Executive Officer, MD & Executive Director

Michele Keryn Dilizia BA (Journ), BSc (Med Sci)CTO

Chief Scientific Director & Executive Director

Justin WardCTO

Principal Quality Chemist & Executive Director

Arthur Kollaras

Principal Engineer & Head of Manufacturing

Alan W. Dunton B.Sc., M.D.CTO

Chief Medical Advisor & Independent Non Executive Director

Justin ReynoldsCFO

Chief Financial Officer

Management

Maggie Niewidok

Company Secretary

John K. A. Prendergast Ph.D.

Executive Chairman of the Board

James Hamilton-Bray Graham GAICDCEO

Chief Executive Officer, MD & Executive Director

Michele Keryn Dilizia BA (Journ), BSc (Med Sci)CTO

Chief Scientific Director & Executive Director

Justin WardCTO

Principal Quality Chemist & Executive Director

Arthur Kollaras

Principal Engineer & Head of Manufacturing

Alan W. Dunton B.Sc., M.D.CTO

Chief Medical Advisor & Independent Non Executive Director

Justin ReynoldsCFO

Chief Financial Officer

Total 8 executives

RCE Frequently asked questions

What is Recce Pharmaceuticals Ltd (RCE) Stock Price?

Current stock price of Recce Pharmaceuticals Ltd (RCE) stock is $0.360. The stock price is +0.00% higher in the session. The intraday range can be seen from this page. Volume of Recce Pharmaceuticals Ltd (RCE) stock is 41.26K.

Last updated at 02 Sept 2026, 06:10 am.

Why is the Recce Pharmaceuticals Ltd (RCE) stock price going up or down today?

The stock price of Recce Pharmaceuticals Ltd (RCE) can change with earnings, company news, and overall market sentiment. Recce Pharmaceuticals Ltd operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Recce Pharmaceuticals Ltd stock expensive at its current price?

Whether Recce Pharmaceuticals Ltd looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for RCE on this page is -3.15. EPS on this page is -0.11. Compare those figures with peers and growth expectations before deciding if the current Recce Pharmaceuticals Ltd price is justified.

How has the stock price of Recce Pharmaceuticals Ltd (RCE) performed historically?

Historical performance for Recce Pharmaceuticals Ltd (RCE) is shown on the price chart on this page. Review multi-period moves alongside volume to see how RCE reacted to past earnings and market events.

Should I buy Recce Pharmaceuticals Ltd (RCE) stock, at this price?

Buying Recce Pharmaceuticals Ltd (RCE) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.